AlzeCure Pharma
4.10.2021 10:21:45 CEST | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / October 4, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the first participant has been dosed in the company's next clinical phase I study (multiple ascending dose, MAD) with the candidate drug ACD856, focused on Alzheimer's disease.
"It is satisfying that the clinical development program is proceeding according to plan and that we have now begun this follow-up phase I study where we will evaluate repeated dosing of ACD856", said Martin Jönsson, CEO of AlzeCure Pharma AB. "In August, we reported data from our SAD phase I study, where we evaluate single administrations of ACD856 at different doses, which showed that the candidate drug has good tolerability and is suitable for further clinical development such as oral treatment of, among other things, Alzheimer's disease. I am very much looking forward to the continued development of ACD856 and in the next step to initiate early efficacy studies".
The MAD phase I study is AlzeCure's third clinical study with ACD856, the lead candidate drug within the company's NeuroRestore platform. ACD856 is being developed as a symptom-relieving treatment for disease states where the cognitive ability is impaired, such as in Alzheimer's disease. The primary study goal is to evaluate ACD856's tolerability and safety after repeated dosing and results from the study are estimated to be available in H1 2022.
The compounds in the NeuroRestore platform stimulate several important signaling pathways in the brain, which, among other things, leads to improved cognition. Preclinical studies have shown that AlzeCure's candidate drugs strengthen the communication between nerve cells and improve cognitive ability, including memory functions.
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se.
About NeuroRestore
NeuroRestore is a platform of symptom-relieving drug candidates for disease states in which cognitive ability is impaired, e.g. Alzheimer's Disease, sleep apnea, traumatic brain injury and Parkinson's disease. NeuroRestore stimulates several important signaling pathways in the brain, which among other things leads to improved cognition. In preclinical studies with NeuroRestore we have been able to show that our drug candidates enhance communication between the nerve cells and improve cognitive ability. NeuroRestore stimulates specific signaling pathways in the central nervous system known as neurotrophins, the most well-known being NGF (Nerve Growth Factor) and BDNF (Brain Derived Neurotrophic Factor). The levels of NGF and BDNF are disturbed in several disease states and the signaling is reduced. The impaired function impairs communication between the synapses, i.e. the contact surfaces of the nerve endings, as well as reducing the possibility of survival for the nerve cells, which gives rise to the cognitive impairments. Neurotrophins play a crucial role for the function of nerve cells, and a disturbed function of BDNF has a strong genetic link to impaired cognitive ability in several different diseases, such as Alzheimer's, Parkinson's disease, traumatic brain injury and sleep disorders. There is also a link between BDNF signaling and depression, something that has been further strengthened in recent years.
About Alzheimer's disease
Alzheimer's disease is the most common form of dementia, affecting approximately 50 million people worldwide. Alzheimer's disease is a lethal disorder that also has a large impact on both relatives and the society. Today, preventive and disease modifying treatments are missing. The main risk factors to develop Alzheimer's are age and genetic causes. Even though the disease can start as early as between 40 and 65 years of age, it is most common after 65 years. Significant investments in Alzheimer research are being made because of the significant unmet medical need and the large cost of this disease for healthcare and society. The total global costs for dementia related diseases is estimated to about 1,000 billion USD. Given the lack of both effective symptomatic treatments and disease modifying treatments, the need for new effective therapies is acute. The few approved drugs on the market today have only a limited symptomatic effect and can produce dose limiting side effects. A disease modifying treatment for Alzheimer's disease is estimated to reach more than $15 billion in annual sales. In Sweden, approximately 100,000 people suffer from Alzheimer's disease with a healthcare cost of about SEK 63 billion yearly, which is more than for cancer and cardiovascular diseases combined.
Image Attachments
Martin Jönsson CEO AlzeCure Pharma
Attachments
AlzeCure's Alzheimer project has initiated the next clinical phase I study with ACD856
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/666613/AlzeCures-Alzheimer-Project-has-Initiated-the-Next-Clinical-Phase-I-Study-with-ACD856
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Human-Robot Collaboration Takes Center Stage at Prestigious Logistics Award30.6.2026 15:00:00 CEST | Press release
Denmark's The Mobile Robot Company wins IFOY Industrial Truck of the Year 2026 with a self-driving pallet jack built to empower warehouse operators rather than replace them. STUTTGART, DE / ACCESS Newswire / June 30, 2026 / In warehouses and factories, much of the work that keeps goods moving is still measured in footsteps. Operators walk the same routes, push the same loads, and repeat the same transport tasks hour after hour. For years, automation has promised to remove that work, but often with a catch: complex projects, fixed infrastructure, long integrations, and systems that assume people should be designed out of the process. At this year's IFOY AWARD, one of intralogistics' most respected technology prizes, the Industrial Truck of the Year award went to a different idea. The Mobile Robot Company, a young Danish robotics startup, won the 2026 title for the J1600 self-driving pallet jack, a robot designed not to replace the warehouse operator, but to work under the operator's dir
RAK ICC Launches New Business Centre in Ras Al Khaimah30.6.2026 14:00:00 CEST | Press release
New initiative creates a dedicated hub for private wealth advisors, family offices and international families in the UAE RAS AL KHAIMAH CITY, AE / ACCESS Newswire / June 30, 2026 / RAK International Corporate Centre (RAK ICC), one of the UAE's leading international corporate registries for private wealth and cross-border structuring, today announced the launch of its new Business Centre in Ras Al Khaimah - a new destination designed specifically for advisors, entrepreneurs, family offices and international families seeking a professional and lasting presence in the UAE. Officially opening on 1 July 2026, the Business Centre reflects RAK ICC's broader vision of creating a more connected and relationship-driven private wealth ecosystem within the emirate. Located within RAK ICC's headquarters, the centre offers convenient access to major transport and commercial hubs, situated approximately 45 minutes from Dubai International Airport and within proximity to Ras Al Khaimah's key business
Affiliate of Pacific Avenue Capital Partners Completes Acquisition of ESE World from Amcor30.6.2026 13:50:00 CEST | Press release
PARIS, FR / ACCESS Newswire / June 30, 2026 / Pacific Avenue Capital Partners ("Pacific Avenue"), a global private equity firm focused on corporate carve-outs and other complex transactions in the middle market, today announced that an affiliate of Pacific Avenue has completed the acquisition of ESE World (the "Company" or "ESE") from Amcor, one of the world's leading packaging companies. ESE is Europe's leading manufacturer of waste and recycling container systems, serving municipalities and businesses globally. The Company produces mobile waste containers, collection banks, hazardous materials containers, and public furnishing solutions from three manufacturing facilities in Germany (Neuruppin and Olpe) and France (Crissey), generating approximately €300m in revenues. Having completed the carve-out from Amcor, ESE will operate as an independent company with the focus and resources to pursue its next phase of growth. Pacific Avenue will work in close partnership with the management te
Multi-Billion-Dollar Global Sports Brand U.S. Polo Assn. Earns Global Awards and Recognitions Across Business, Sport, and Content Categories30.6.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / June 30, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), continues to gain global momentum in 2026, earning a series of high-profile honors and recognitions that reflect the brand's expanding footprint, deepening consumer trust, and growing influence in sports-driven content and storytelling. Among U.S. Polo Assn.'s top recognitions this year, the global, multi-billion-dollar brand was honored at the 11th Annual 2026 Globee Awards for Achievement with Gold for the "Global Expansion" category and Silver for the "Brand Development" category. These awards highlight U.S. Polo Assn.'s ability to scale its authentic, sport-inspired brand across more than 190 countries while building a consistent and relevant brand in diverse markets worldwide. The recognition follows a record-setting $2.7 billion in global retail sales in 2025, reinforcing the brand's continued upward trajectory. Trust and consumer credi
Tenstorrent Sets New Performance Records, Launches TT- Ascalon S, and Expands Across Japan30.6.2026 08:30:00 CEST | Press release
At TT-Deploy JP, Tenstorrent set new records on language and video models, launched TT-Ascalon S RISC-V CPU IP for agentic AI, and joins ai&'s sovereign heterogenous inference platform with Tenstorrent Galaxy™ superclusters, a general-purpose system that can drop in beside GPUs or stands alone. TOKYO, JP / ACCESS Newswire / June 30, 2026 / Tenstorrent, the AI compute company led by CEO Jim Keller, today at TT-Deploy JP set new performance records across language and video, launched TT-Ascalon S RISC-V CPU IP for agentic AI, and detailed its largest deployment to date, a general-purpose, heterogenous AI build in Japan. Each rests on the same foundation: a single architecture that runs major AI workloads faster than GPUs and scales from a licensable core to a Tenstorrent Galaxy™ supercluster over standard Ethernet. That makes Tenstorrent's Networked AI architecture a different kind of solution - open, general-purpose, flexible for heterogeneous or stand alone deployments, and backed by A
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom